Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» U.S. House Approves Restrictions on Brand-Name Drug Agreements
U.S. House Approves Restrictions on Brand-Name Drug Agreements
U.S. House Approves Restrictions on Brand-Name Drug Agreements
Submitted by
admin
on July 2, 2010 - 9:39am
Source:
Bloomberg Businessweek
News Tags:
pay-for-delay
healthcare reform
Headline:
U.S. House Approves Restrictions on Brand-Name Drug Agreements
Do Not Allow Advertisers to Use My Personal information
